

Lexaria Bioscience Corp.

08:20 24 Jul 2019

Lexaria Bioscience, Hill Street Beverage sign 10-year joint manufacturing partnership for DehydraTech products

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) and Hill Street Beverage Company Inc (CVE:BEER) announced Wednesday that they have entered into a joint manufacturing partnership to produce DehydraTech products, including THC and CBD powder.

Under the partnership, which is valid for 10 years, the powder will be used to produce consumer products like tablets, capsules, or packets for sale in Canada and for export where permitted. Also, the powder will be sold in bulk to licensed producers.

Manufacturing will be done at Hill Street's soon-to-be-acquired OneLeaf Cannabis cultivation and processing facility in Regina, Saskatchewan, pending licensing by Health Canada.

Hill Street will own and manage all aspects of the manufacturing business under Lexaria's own license and patents for DehydraTECH and its related processes. Profits from this business unit will be shared equally between Hill Street and Lexaria, based in Kelowna, British Columbia.

READ: Lexaria Bioscience is seeing increased demand for its DehydraTECH drug delivery system

A novel drug-delivery platform, Lexaria created DehydraTECH to mask unwanted tastes, improve onset speed and increases the bioavailability of active pharmaceutical ingredients in a simple and cost-effective platform.

It allows drugs and vitamins - in the case of cannabis, CBD and THC - to enter the bloodstream faster than existing drug delivery platforms.

The partnership will, for the first time ever, permit intermediate ingredients made from cannabis processed by Lexaria's DehydraTECH to be legally sold within Canada on a business-to-business basis between licensed producers and others licensed by Health Canada to manufacture cannabis-infused edibles, including both THC and CBD.

READ: Hill Street makes big bet on cannabis-infused drinks

Hill Street, which is gearing up to produce its own line of cannabis-infused beverages, has acquired two global semi-exclusive licenses to utilize the DehydraTECH THC beverage infusion technology, and to use the DehydraTECH CBD infusion technology around the world for 10 years. This expands a 2018 license award to Hill Street to use DehydraTECH for THC beverages in Canada only,

Under the terms of the agreement, Toronto-based Hill Street will pay up to US\$1,800,000 to Lexaria by issuing US\$800,000 in common shares to the company at the lower market price on the day prior to the announcement of the agreement, or C\$0.23 per share. Lexaria will issue US\$250,000 in restricted common shares to Hill Street.

Price: 0.33

Market Cap: \$29.56 m

1 Year Share Price Graph



Share Information

Code: LXX

Listing: CSE

52 week	High	Low
	1.27	0.31

Sector: Cannabis

Website: www.lexariabioscience.com

Company Synopsis:

Lexaria Bioscience Corp has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. Many vitamins, drugs, supplements and other beneficial molecules are lipophilic (i. e.

action@proactiveinvestors.com

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter [@PatrickMGraham](https://twitter.com/PatrickMGraham)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).